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Abstract The possible regulation of the expression of uncou-
pling protein-2 (UCP2) mRNA by thyroid hormones in different 
tissues was examined in rats. Triiodothyronine (T3) was found to 
produce an organ-specific enhancement of UCP2 expression in 
rat tissues. The effect of T3 was markedly observed in heart, 
whereas a moderate effect was seen in skeletal muscle and no 
effect in kidney or liver. These results suggest that UCP2 is a 
protein that may be involved in the nuclear-mediated effect of T3 
on resting metabolic rate in the rat. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The thyroid hormones exert a wide variety of biological 
actions. It is well known that they induce metamorphosis in 
amphibia and play a fundamental role in regulating mamma-
lian development and energy metabolism. Administration of 
T3 to hypothyroid rats leads to a significant increase in the 
metabolic rate of the whole animal after 36-72 h. At the 
mitochondrial level a stimulation of respiration can be ob-
served as a result of an increased activity in the respiratory 
chain and an increase in oxidative phosphorylation [1]. 
The effects of thyroid hormones on mitochondrial activity 
may be divided into 'short-term' and 'long-term' effects. The 
'short-term' effects are probably mediated by a direct interac-
tion of diiodothyronines with mitochondria and possibly with 
non-catalytic subunits of the cytochrome oxidase complex as 
previously hypothesized by us [2,3]. The 'long-term' effects are 
mediated by T3 and involve the nuclear pathway (for review 
see [4]). The early studies of Tata and Widnell [5] resulted in 
the first proposal that thyroid hormones exert their actions 
primarily by a stimulation of the transcription of genetic in-
formation at the nuclear level. The exact molecular mecha-
nisms underlying these effects are poorly understood, 
although it seems that some of them can be attributed, at 
least in part, to the induction of nuclear encoded mitochon-
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iopanoic acid; N, euthyroid control rats; P+l, rats made hypothyroid 
by a combined treatment with PTU and IOP for 3 weeks; ID-I, type I 
deiodinase activity; ID-II, type II deiodinase activity; ID-Ill, type III 
deiodinase activity 
drial proteins such as cytochrome c [6], cytochrome c\ [7], 
adenine nucleotide translocase and glycerol 3-phosphate de-
hydrogenase [8]. Recently, however, the discovery that, be-
sides the uncoupling protein present in brown adipose tissue 
(termed UCPi), two other uncoupling proteins (termed UCP2 
and UCP3) are expressed in several tissues in humans and rats 
[9-12] has opened new, interesting perspectives in research on 
the regulation of energy metabolism. Uncoupling proteins 
produce heat by generating a pathway that allows dissipation 
of the proton electrochemical gradient across the inner mito-
chondrial membrane without a coupling to any other energy-
consuming process. In mice, UCP2 is present in metabolically 
very active tissues such as heart, kidney, skeletal muscle and 
liver (the last two at a lower level) and it has been suggested 
that UCP2 plays a role in energy balance [9]. 
It has been shown that mitochondria from numerous tissues 
are 'imperfectly coupled' as a consequence of a proton leak 
that could account for as much as 15-33% of cellular energy 
expenditure; thyroid hormone seems to influence this mito-
chondrial proton leak (for review see [13]). It is conceivable 
that thyroid hormones might do this by regulating the expres-
sion of uncoupling proteins. Consequently, we thought it 
might be interesting to investigate in the rat the role played 
by thyroid hormones (T4 and T3) in the regulation of the 
expression of UCP2 in metabolically active tissues such as 
liver, heart, skeletal muscle and kidney. In order to discrim-
inate between the effects of T4 and T3, these hormones were 
injected separately into both normal euthyroid rats and rats in 
which hypothyroidism was induced by administration of pro-
pylthiouracil (PTU) and iopanoic acid (IOP). This combined 
treatment produces animals with severe hypothyroidism and 
with a strong inhibition of all three known types of deiodinase 
enzymes. 
2. Materials and methods 
2.1. Rat treatments and tissue samples 
Male Wistar rats (220-230 g) living in a temperature-controlled 
room at 28°C were kept, one per cage, under an artificial lighting 
regime of 12 h light: 12 h darkness. A commercial mash was available 
ad libitum and the animals had free access to water. Hypothyroidism 
was produced in rats by a daily i.p. administration of PTU (1 mg/100 
g body weight) for 3 weeks together with a weekly i.p. administration 
of IOP (6 mg/100 g body weight). Euthyroid controls were sham 
injected with saline. 
Chronic hyperthyroidism was induced in euthyroid and hypothy-
roid rats by seven daily i.p. injections of either 30 ug T4/IOO g body 
weight or 15 |ig T3/IOO g body weight; control rats (euthyroid and 
hypothyroid) received saline injections. The iodothyronine doses and 
the treatment duration were chosen to obtain a change in the levels of 
the thyroid hormones without significantly changing the body weight 
of the animals. At the end of the treatments (24 h after the last dose of 
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T4 or T3), rats were anesthetized by i.p. administration of chloral 
hydrate (40 mg/100 g body weight) and killed by decapitation. Trunk 
blood was collected and serum was isolated and stored at — 20°C until 
hormone levels were to be analyzed. 
The liver, heart, skeletal muscles (hind leg muscles), kidneys, brown 
adipose tissue and brain were isolated from each rat, immediately 
frozen in liquid nitrogen, then stored at — 80°C until further process-
ing. All experiments were performed in accordance with local and 
national guidelines covering animal experiments. 
2.2. Deiodmase assays and determination of hormone concentrations 
Type I deiodinase activity (ID-I) was determined in the liver micro-
somal fraction by analysis of the production of radioiodide from out-
er-ring-labeled rT3. To this end, 0.1 uM rT3 and = 100000 cpm [3',5'-
i25jjrj3 Were incubated for 30 min at 37°C with 2 ug microsomal 
protein in 200 ul of 0.2 M phosphate buffer (pH 7.2), 4 mM EDTA 
and 5 mM dithiothreitol (DTT), using the method described by others 
[14]. 
Type II deiodinase activity (ID-II) was determined in BAT accord-
ing to the method of Leonard et al. [15]. This involved measuring the 
release of radioiodide from [3',5'-125I]rT3 following the incubation of 
20 ug BAT infranatant proteins for 60 min at 37°C with 2 nM rT3 
and ~ 100000 cpm [3',5'-125I]rT3 in 200 ul of 0.1 M phosphate buffer 
(pH 7.2), 2 mM EDTA and 20 mM DTT. In both the type I and type 
II deiodinase assays, the reactions were stopped by the addition of 100 
ul 5% bovine serum albumin at 0°C. Protein-bound iodothyronines 
were precipitated by the addition of 500 ul of 10% (w/v) trichloro-
acetic acid. After incubation of the mixtures at 0°C for 10 min, they 
were centrifuged and the radioactivity in the supernatant subsequently 
determined. Enzymatic deiodination was corrected for non-enzymatic 
125I production (as determined in blank incubations without enzymes) 
and multiplied by 2 to account for random labeling and the deiodi-
nation of the 3' and 5' positions in [3',5'-125I]rT3. 
Type III deiodinase activity (ID-III) was determined in brain micro-
somes by measuring the formation of 3[3'-125I]T2 from [3'-125I]T3 by 
HPLC analysis, as reported by Schoenmakers et al. [16]. A 100 ug 
sample of brain microsomal protein was incubated for 60 min at 37°C 
with 1 nM T3 and = 100000 cpm [3'-
125I]T3 in phosphate buffer (pH 
7.2) with 4 mM EDTA and 10 mM DTT. The reactions were stopped 
by the addition of 300 JJ.1 methanol on ice. After centrifugation of 
precipitated proteins, the supernatants were analyzed for 3[3'-125I]T2 
formation by HPLC analysis following elution with a 45:50 (v/v) 
mixture of methanol and 20 mM ammonium-acetate (pH 4.0) at a 
flow rate of 0.8 ml/min. 
The protein concentration was determined by the method of Har-
tree [17] using bovine serum albumin as standard. 
Serum levels of T3 and T4 (in unextracted sera) were estimated by 
means of specific RIAs using reagents and protocols supplied by Bec-
ton-Dickinson (Orangeburg, NJ, USA). 
2.3. RNA isolation and Northern blotting 
Total RNAs from skeletal muscle, liver, heart and kidney were 
purified by the method of Chomczynski and Sacchi [18]. For Northern 
blots, 20 ug of total RNA was separated on a 1% (w/v) agarose/form-
aldehyde gel and transferred onto nylon membranes with 20XSSC 
(1 XSSC= 150 mM NaCl, 15 mM sodium citrate, pH 7.0). 
To detect specific mRNA, we used a 900 bp probe derived from 
murine UCP2 cDNA (GenBank accession number U69135 [9]) which 
was labeled with 32P using a random priming system. 
Hybridization and washing were carried out as described by Church 
Fig. 1. A: Expression levels of UCP2 mRNA in the heart of hypo-
thyroid rats (left panel) and normal euthyroid rats (right panel) be-
fore and after T4 and T3 administration. B: Hybridization with a 
28S-derived oligonucleotide. The Northern blotting procedures are 
described in Section 2. Lines: 1, 2 = hypothyroid rats; 3, 4 = hypo-
thyroid rats treated with T3; 5, 6 = hypothyroid rats treated with 
T4; 7 = normal euthyroid rats; 8 = normal euthyroid rats treated 
with T3; 9 = normal euthyroid rats treated with T4. 
and Gilbert [19]. A 28S-derived oligonucleotide was used to normalize 
the amount of RNA for each line. 
3. Results 
Table 1 shows the effects of 3 weeks' treatment with PTU 
and IOP on total serum T4 and T3 levels, as well as on de-
iodinase activities. The combined administration of PTU and 
IOP produces rats with severe hypothyroidism: the total T3 
and T4 levels are, in fact, significantly lower in such hypo-
thyroid rats than in euthyroid ones. Another effect of the 
PTU+IOP treatment is to inhibit the activities of all three 
deiodinase enzymes: they were strongly inhibited ( > 80% 
for type III and > 91% for type I) or, in the case of type II 
deiodinase, greatly reduced (by 64%). 
In our conditions, T3 greatly influenced the expression of 
UCP2 mRNA in heart, had a weaker effect in skeletal muscle, 
but was almost ineffective in kidney and liver. 
In hypothyroid rats, UCP2 mRNA was weakly expressed in 
heart and, while the administration of T3 strongly enhanced 
its expression, administration of T4 was much less effective 
(see Fig. 1, left panel). When T4 and T3 were injected into 
normal euthyroid rats, the differences between T4- and T3-
treated animals were not so evident (see Fig. 1, right panel). 
In skeletal muscle, the situation was quite different. In hy-
pothyroid rats, UCP2 mRNA expression was not evident until 
after the administration of T3 and T4 (see Fig. 2, left panel). 
In normal euthyroid animals, a slight expression of UCP2 
mRNA was already evident, and administration of T3 induced 
a stimulation of its expression. The administration of T4 to 
normal euthyroid animals also enhanced the expression of 
Table 1 
T3 and T4 serum 
Parameter 
levels, liver ID-I activity, BAT ID-II activity and brain ID-III activity in hypothyroid (P+I) and euthyroid (N) rats 
Group 
T3 (nmol/1) 
T4 (nmol/1) 
ID-I activity (pmol I/min/mg prot) 
ID-II activity (fmol I/h/mg prot) 
ID-III activity (fmol 3,3'-T2/min/mg prot) 
P+I 
0.2510.02* 
8.8 ±0.98* 
22 ±2* 
16 ± 1 * 
4 ± 1 * 
N 
0.9510.08 
45 ±3 
240 ±14 
44 ±3 
28 ±1 
Results are presented as mean ± S.E. of values from four rats in each group. Deiodinase activity is the mean of values from four experiments, each 
performed in triplicate. *P < 0.05 vs. N rats. 
P+I = rats made hypothyroid by a combined treatment with PTU and IOP for 3 weeks. N = euthyroid control rats. 
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UCP2 m R N A , but to a lesser extent (see Fig. 2, right panel). 
In the kidney from hypothyroid rats, U C P 2 m R N A was 
moderately expressed, but thyroid hormones seemed not to 
have a significant influence on its expression (see Fig. 3). Sim-
ilar results were obtained in normal euthyroid rats (data not 
shown). 
In the whole liver, UCP2 m R N A was poorly expressed in 
both normal and hypothyroid rats (in accordance with the 
reports of Fleury et al. [9] and Larrouy et al. [20]). Neither 
T3 nor T4 had any apparent effect on its expression under our 
conditions (data from normal euthyroid rats are not shown). 
4. Discussion 
Energy balance is a delicate equilibrium between energy 
intake and energy expenditure. Significant advances have 
been made in the last few years in the understanding of the 
highly complex processes underlying the control of energy 
intake. This control is now known to involve multiple neural 
circuits with specific neuropeptides and neurotransmitters all 
influenced by peripheral signals (such as leptin) and inputs 
from higher cortical centers. In contrast, much less is known 
about the molecular mechanisms involved in the regulation of 
energy expenditure. However, the discovery of UCP2 and the 
possibility of the regulation of its expression by thyroid hor-
mones opens a new line of enquiry in this field. In this report, 
we identify T 3 (and to a lesser extent, T4) as the first hormo-
nal factor that has been found to regulate the expression of 
UCP2. To judge from the present study in the rat, the control 
exerted by T 3 is organ-specific, the greatest effect being seen in 
the heart, a clear effect in skeletal muscle (especially in normal 
euthyroid animals), and no effect at all in kidney and liver. 
F r o m the data presented here, it is evident that the heart 
preferentially utilizes T3 for the control of UCP2 expression 
and that it is normally derived from T4. In fact, in hypothy-
roid rats the effect exerted in the heart by T 3 is stronger than 
that of T4 , while in normal euthyroid rats the effects due to T4 
and T 3 are almost equal. This difference may be explained by 
the greater conversion of injected T4 to T3 by deiodinase 
enzymes in euthyroid rats. In our hypothyroid rats, the deio-
dinase enzymes are strongly inhibited, and so the above con-
version would be correspondingly reduced. The data from 
skeletal muscle suggest that this tissue utilizes T 3 collected 
from the serum, rather than relying on that produced in the 
tissue by the conversion of T4 to T3. 
muscle 
liver 
A 
B 
1 2 
. 
3 4 
■ * * S 
5 6 
* * i 
.., 
W«w 
7 8 9 
Fig. 2. A: Expression levels of UCP2 mRNA in the skeletal muscle 
of hypothyroid rats (left panel) and normal euthyroid rats (right 
panel) before and after T4 and T3 administration. B: Hybridization 
with a 28S-derived oligonucleotide. The Northern blotting proce-
dures are described in Section 2. Lines: 1, 2 = hypothyroid rats; 3, 
4 = hypothyroid rats treated with T3; 5, 6 = hypothyroid rats treated 
with T4; 7 = normal euthyroid rats; 8 = normal euthyroid rats 
treated with T3; 9 = normal euthyroid rats treated with T4. 
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Fig. 3. A: Expression levels of UCP2 mRNA in the kidney (right 
panel) and liver (left panel) of hypothyroid rats before and after T4 
and T3 administration. B: Hybridization with a 28S-derived oligo-
nucleotide. The Northern blotting procedures are described in Sec-
tion 2. Lines: 1, 2 = hypothyroid rats; 3, 4 = hypothyroid rats treat-
ed with T3; 5, 6 = hypothyroid rats treated with T4. 
The discovery of the role played by T 3 in controlling the 
expression of UCP2 casts a new light on the problem of the 
nuclear-mediated regulation of energy expenditure by thyroid 
hormones. Such effects may be especially important in some 
specific circumstances such as fasting or cold exposure, in 
which variations in the circulating levels of thyroid hormones 
have been observed [21,22]. This idea is consistent with a 
recent finding by Boss et al. [23] of a tissue-dependent upreg-
ulation of U C P 2 expression in the rat in response to fasting 
and cold. 
Previous reports have shown that thyroid hormones stim-
ulate the mitochondrial proton leak (for review see [13]) and 
our results may suggest a molecular basis for this effect in 
skeletal muscle and heart. 
In conclusion, the upregulation of UCP2 m R N A expression 
is in agreement with the known role of thyroid hormones in 
resting metabolic rate and the genetic linkage of the UCP2 
locus to resting metabolic rate value in man [24]. 
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